Long Term Outcomes of COVID-19 Associated Cystitis (CAC)

Document Type

Conference Proceeding

Publication Date


Publication Title

Journal of Urology


INTRODUCTION AND OBJECTIVE: COVID-19 associated cystitis (CAC) is a newly-described condition associated with new onset or exacerbations of baseline urinary symptoms (e.g. overactive bladder(OAB) symptoms) that may present as a manifestation of Long COVID. Little is known on the management and long-term outcomes for patients suspected of having CAC. In this study we aim to assess the long term efficacy of conservative OAB the on their symptoms. METHODS: In this prospective cohort study, we identified patients with CAC 10-14 weeks following discharge from 2 academic downtown Detroit hospitals with new or worsening OAB during 5/22/2020 to 12/31/2020. Symptoms were assessed at baseline and at 21-28 months post-discharge using the AUA's 5 symptom OAB assessment tool and 4 quality-of-life (QoL) symptoms, based on gender and changes in urinary symptom status. RESULTS: A total of 350 patients with CAC were identified, of which 250 (71%) had new onset, and 100 (29%) had worsening OAB symptoms after COVID hospitalization (Table 1). Follow up at 21-28 months revealed significant decreases in median OAB and QoL scores for all groups (Table 2). Overall, 270 (87%) of the 310 patients improved with standard therapies (e.g. behavioral modification), with a decrease in the OAB and Qol score from 18 and 19 to 7 and 8respectively. Of the 250 patients with new onset symptoms, 220(95.4%) had improvement in symptoms, whereas, of those with existing OAB symptoms only 60 (60.7%) improved. In the later, OAB and Qol scores decreased by 6 points compared with 9-10 in the new onset group, with a lack of return to baseline status. No differences were noted among improvements in symptoms between females and males. CONCLUSIONS: We hereby report the first long-term follow-up of patients who developed CAC and assessed the prognosis of CAC in Long COVID. We found that after 21-28 months, only 13% (40/310) of patients had persistent lower urinary tract symptoms. Patients with Long COVID and CAC may be reassured that symptoms resolves in vast majority of cases and that supportive and reversible treatment should be recommended





First Page


Last Page



American Urological Association Annual Meeting, April 28 - May 1, 2023, Chicago, IL